Decentrialz logo
  • HIPAA Compliant
  • ISO 27001 Certified
Find Trials
About UsContact
Become a Volunteer+1 877 705 1914

Status:

COMPLETED

Antiretroviral Therapy for Advanced HIV Disease in South Africa

Lead Sponsor:

National Institutes of Health Clinical Center (CC)

Conditions:

HIV

Eligibility:

All Genders

14+ years

Phase:

PHASE4

Brief Summary

This study will determine how well four different antiretroviral drug therapies work in patients with advanced HIV disease. The trial is part of the South Africa-U.S. Project Phidisa Programme - a col...

Detailed Description

This is a randomized, open label 2x2 factorial study of four regimens of initial therapy. I. AZT + ddl + EFV II. AZT + ddl + r/LPV III. D4T + 3TC + EFV IV. D4T + 3TC + r/LPV Eligible patients wil...

Eligibility Criteria

Inclusion

  • INCLUSION CRITERIA:
  • Uniformed SANDF personnel or family members of SANDF personnel who are registered as eligible for health services from the SAMHS.
  • HIV positive as diagnosed and/or confirmed in PHIDISA I OR documented HIV infection from an accredited source.
  • CD4+ cell count less than 200 cells/microL (or less than or equal to 14% for patients post-splenectomy) AND/OR any AIDS defining illness currently or historically. Patients with pulmonary tuberculosis must have a CD4+ cell count less than 200 cells/microL. Patients with KS must have a CD4+ cell count less than 200 cells/microL unless their sarcoma is progressive and/or requires chemotherapy.
  • Antiretroviral treatment naive (less than 7 days cumulative exposure to any antiretroviral drug) or treated for post-exposure prophylaxis without becoming HIV infected at that time.
  • Laboratory variables as follows:
  • Haemoglobin greater than or equal to 9.0g/dL for men and greater than or equal to 8.0g/dL for women.
  • Absolute neutrophil count greater than or equal to 500 cells/microL.
  • Platelet count greater than or equal to 25,000/mm(3).
  • Serum transaminase (ALT or AST) less than or equal to 5 times upper limit of normal (ULN).
  • 14 years or older.
  • Likely to be compliant with study procedures and clinical visits in the opinion of the clinical investigator (guidance is provided in the protocol to assist clinicians in making this decision).
  • Have completed the PHIDISA treatment adherence counseling session.
  • Provision of written informed consent.
  • EXCLUSION CRITERIA:
  • Any history of pancreatitis or serious pathology indicative of increased risk for pancreatitis.
  • Current requirement for use of a medication that is contra-indicated with the PHIDISA II study drugs. Where possible, alternate therapies should be selected in order to facilitate randomization. Patients entering the study with tuberculosis should defer screening and randomization until successful completion of an induction course of anti-mycobacterium therapy including rifampicin. As appropriate this patient could recommence screening when starting the maintenance regimen of anti-tubercular drugs excluding rifampicin.
  • Pregnancy (following delivery, such women may be enrolled).

Exclusion

    Key Trial Info

    Start Date :

    January 1 2004

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    August 1 2008

    Estimated Enrollment :

    1771 Patients enrolled

    Trial Details

    Trial ID

    NCT00342355

    Start Date

    January 1 2004

    End Date

    August 1 2008

    Last Update

    May 21 2013

    Active Locations (7)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 2 (7 locations)

    1

    South African Military Health Services (SAMHS)

    Centurion, South Africa

    2

    Umtata Sickbay

    Eastaern Cape, South Africa

    3

    3 Military Hospital

    Free State, South Africa

    4

    1 Military Hospital

    Gauteng, South Africa